Figure 6
Figure 6. ALPS “DNT-like” CD4+and CD8+ T cells show enhanced mitotic activity and mTOR signaling. CD4+ and CD8+ T cells of ALPS patients were gated for naive (CD45RA+/CD57−), TEMRA (CD57+/CD28−/CD27−), and “DNT-like” (CD57+/CD28+/CD27+) cells and analyzed for their Ki67 expression (A) or phosphorylation status after stimulation with anti-CD3/CD28 mAbs (B). Plots show representative data from 1 of 3 independent experiments with similar results. Y-axis in the histograms is normalized to mode. (C) PBMC from patients with ALPS before and under rapamycin therapy were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD28, anti-CD57, and anti-Ki67 mAbs. Cells are gated for CD3+/CD4+ and CD3+/CD4+/CD57+ (left) or CD3+/CD8+ and CD3+/CD8+/CD57+/CD28− (right). Representative plots show data of a patient with ALPS before and during rapamycin therapy; graphs present frequencies of 3 patients.

ALPS “DNT-like” CD4+and CD8+ T cells show enhanced mitotic activity and mTOR signaling. CD4+ and CD8+ T cells of ALPS patients were gated for naive (CD45RA+/CD57), TEMRA (CD57+/CD28/CD27), and “DNT-like” (CD57+/CD28+/CD27+) cells and analyzed for their Ki67 expression (A) or phosphorylation status after stimulation with anti-CD3/CD28 mAbs (B). Plots show representative data from 1 of 3 independent experiments with similar results. Y-axis in the histograms is normalized to mode. (C) PBMC from patients with ALPS before and under rapamycin therapy were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD28, anti-CD57, and anti-Ki67 mAbs. Cells are gated for CD3+/CD4+ and CD3+/CD4+/CD57+ (left) or CD3+/CD8+ and CD3+/CD8+/CD57+/CD28 (right). Representative plots show data of a patient with ALPS before and during rapamycin therapy; graphs present frequencies of 3 patients.

Close Modal

or Create an Account

Close Modal
Close Modal